SUBSCRIBE: Print / eNewsletter
Treatment with lenalidomide and rituximab improved progression-free survival, compared with placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma.
Lisocabtagene maraleucel induced high response rates in patients with aggressive relapsed/refractory large B-cell lymphoma.
The combination use of polatuzumab-vedotin, obinutuzumab, and lenalidomide showed high complete response rates in patients with relapsed/refractory follicular lymphoma.
The CAR T-cell therapy axicabtagene ciloleucel induced a median overall survival of 25.8 months for patients with refractory large B-cell lymphoma.
Mosunetuzumab generated durable responses in patients with highly refractory non-Hodgkin lymphomas.
Tanya Siddiqi, MD, discussed the CAR T-cell trial ahead of the ASH Annual Meeting & Exposition in an interview with CancerNetwork®.
Research on chimeric antigen receptor T-cell therapy to be presented at the ASH Annual Meeting & Exposition is set to address drawbacks associated with treatment.
Researchers compared the ability of a novel prognostic score vs existing scores to identify patients with high-risk DLBCL.
The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting & Exposition.
Research presented at ASH 2018 examined whether checkpoint blockade therapy sensitizes patients with relapsed/refractory NHL to consequent treatment.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
